Results 41 to 50 of about 98,908 (319)

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study [PDF]

, 2015
Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCγ receptor, DNA repair and detoxification genes ...
Angrilli, Francesco, Arcaini, Luca, Bertoldero, Giovanni, Bruscaggin, Alessio, Ciabatti, Elena, FEDERICO, Massimo, Gaidano, Gianluca, Galimberti, Sara, La Cava, Piera, LUMINARI, Stefano, Merli, Francesco, Palumbo, Giuseppe A., Pulsoni, Alessandro, Rigacci, Luigi, Rossi, Davide, Rusconi, Chiara, Spina, Michele, Stelitano, Caterina, Tucci, Alessandra, Vallisa, Daniele   +19 more
core   +2 more sources

Follicular lymphoma

Annals of Oncology, 2010
Follicular lymphoma is an indolent and usually incurable disease. It has been therefore traditionally approached either by watch and wait or with single-agent treatments. The purpose was to maintain a good quality of life for a prolonged time. More aggressive regimens, including polychemotherapy, high-dose chemotherapy with stem-cell rescue and the ...
openaire   +3 more sources

IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications [PDF]

, 2019
The precise B cell of origin and molecular pathogenesis of nodal marginal zone lymphoma (NMZL) remain poorly defined. To date, due to the rarity of NMZL, the vast majority of already-published studies have been conducted on a limited number of samples ...
Amato, Teresa, Aversa, Sara, Bellan, Cristiana, Cencini, Emanuele, Cevenini, Gabriele, DI NAPOLI, Arianna, Di Stefano, Gioia, Giulio Carta, Alberto, Granai, Massimo, Kovalchuk, Sofya, Lazzi, Stefano, Leoncini, Lorenzo, Mancini, Virginia, Santi, Raffaella, Vergoni, Federica, Ziepert, Marita   +15 more
core   +2 more sources

Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report

Journal of Medical Case Reports, 2020
Background High-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 is an aggressive mature B-cell neoplasm, whereas B-lymphoblastic lymphoma is immature cell proliferation, with a frequent positivity for terminal deoxynucleotidyl ...
Antonin Bouroumeau, Eleonore Kaphan, Clémentine Legrand, Tatiana Raskovalova, Gautier Szymanski, Claire Vettier, Christine Lefebvre, Marie-Christine Jacob, Anne McLeer, Michel Peuchmaur, Rémy Gressin, Hervé Sartelet   +11 more
doaj   +1 more source

Use of Rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas [PDF]

, 2011
The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of ...
Fozza, Claudio, Longinotti, Maurizio Roberto   +1 more
core   +4 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse—a case report

Journal of the Egyptian National Cancer Institute, 2020
Background Transformation of low-grade follicular lymphoma to high-grade diffuse large B cell lymphoma (DLBCL) is known. However, the opposite is not commonly reported.
M. C. Suresh Babu, Antony George Francis Thottian, D. Lokanatha, Linu Abraham Jacob, K. N. Lokesh, A. H. Rudresha, L. K. Rajeev, Saldanha Smitha, Syed Adil Hassan, Khandare Pravin Ashok, C. S. Premalatha, M. N. Suma   +11 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

Microphysiological Systems of Lymphatics and Immune Organs

Advanced Healthcare Materials, EarlyView.
This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain, Ankur Singh, Andrés J. García   +2 more
wiley   +1 more source